GlassScriptPhysician profile
Edward L Riceberg
NPI 1861558173
$574.74
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $88.64 · 2021: $188 · 2022: $29.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.48 | 2019 | |
| Abbvie INC. | $49.88 | 2021 | |
| Mallinckrodt Enterprises LLC | $49.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $48.69 | 2019 | |
| Lilly USA, LLC | $47.41 | 2019-2021 | |
| Amgen INC. | $41.74 | 2019-2020 | |
| Eisai INC. | $30.65 | 2021 | |
| Mallinckrodt Hospital Products INC. | $29.89 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.98 | 2021 | |
| Philips North America LLC | $21.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.78 | 2020 | |
| Astellas Pharma US INC | $20.75 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.41 | 2021 | |
| Circassia INC. | $18.93 | 2019 | |
| Adlon Therapeutics L.P. | $18.45 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.84 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.34 | 2020 | |
| Allergan, INC. | $15.95 | 2020 | |
| Novo Nordisk INC | $15.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Riceberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.